NCT04720963 is a Phase 4 clinical trial of Remimazolam in Sedative; Anxiety Disorder, sponsored by Second Affiliated Hospital of Wenzhou Medical University.

Who is sponsoring NCT04720963?

NCT04720963 is sponsored by Second Affiliated Hospital of Wenzhou Medical University.

What drugs are being tested in NCT04720963?

Interventions in NCT04720963: Remimazolam, Distilled water for injection, Dexmedetomidine.

What condition does NCT04720963 study?

NCT04720963 studies Sedative; Anxiety Disorder.

Is NCT04720963 still recruiting?

NCT04720963 is currently completed. Last updated 8 September 2023.

Last reviewed 2023-09-08 · How we verify

NCT04720963

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal Remimazolam for Premedication in Pediatric Patient

Completed Phase 4 Last updated 8 September 2023

What this trial tests

Phase 4 trial testing Remimazolam in Sedative; Anxiety Disorder in 90 participants. Completed in 28 February 2022.

Timeline

7 February 2021

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Second Affiliated Hospital of Wenzhou Medical University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	90
Start date	7 February 2021
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	1 location across China

Drugs / interventions tested

Remimazolam — full drug profile →
Distilled water for injection
Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

Sedative; Anxiety Disorder — all drugs for Sedative; Anxiety Disorder →

Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Who can join

Adults 2 to 5, any sex, with Sedative; Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anesthetic inhalation induction could be one of the most stressful experiences for children during the perioperative period, with almost 50% of them showing anxiety. It is an essential challenge for pediatric anesthesiologists on how to decrease anxiety for children in the operating room (OR) environment and to facilitate a smooth induction of anesthesia. Various factors like parental separation, unfamiliar surroundings, fear of physicians and needle injections can increase their preoperative anxiety. The researchers conducted the current study to investigate whether intranasal remimazolam can reduce anxiety in children before surgery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.
Kim KM. · · 2022 · cited 161× · PMID 35139608 · DOI 10.17085/apm.21115
Remimazolam: An Updated Review of a New Sedative and Anaesthetic.
Hu Q, Liu X, Wen C, Li D, et al · · 2022 · cited 120× · PMID 36411859 · DOI 10.2147/dddt.s384155
Preoperative Anxiolytic and Sedative Effects of Intranasal Remimazolam and Dexmedetomidine: A Randomized Controlled Clinical Study in Children Undergoing General Surgeries.
Cai YH, Wang CY, Fang YB, Ma HY, et al · · 2024 · cited 14× · PMID 38774484 · DOI 10.2147/dddt.s461122
Effective and safe pediatric sedation.
Jang YE, Kim JT. · · 2024 · cited 4× · PMID 39069650 · DOI 10.17085/apm.24046

Verify or expand the search:

Other trials of Remimazolam

Trials testing the same drug.

NCT07251101 — Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery · NA · not yet recruiting
NCT07459322 — The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy · NA · not yet recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other Second Affiliated Hospital of Wenzhou Medical University trials

Trials by the same sponsor.

NCT07466511 — Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis · NA · not yet recruiting
NCT07530848 — Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients · not yet recruiting
NCT07346443 — Mechanism Study of G Protein-coupled Receptor 81 in Multiple Organ Dysfunction of Heat Stroke · not yet recruiting
NCT07353970 — Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro- · not yet recruiting
NCT07332793 — Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04720963 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Wenzhou Medical University
Last refreshed: 8 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing